Clinical Trials About "4107 Zotarolimus Eluting Coronary Stent Arterial Occlusive Diseases" RSS

16:59 EDT 1st September 2014 | BioPortfolio

We list hundreds of Clinical Trials about "4107 Zotarolimus Eluting Coronary Stent Arterial Occlusive Diseases" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "4107 Zotarolimus Eluting Coronary Stent Arterial Occlusive Diseases" on BioPortfolio

We have published hundreds of 4107 Zotarolimus Eluting Coronary Stent Arterial Occlusive Diseases news stories on BioPortfolio along with dozens of 4107 Zotarolimus Eluting Coronary Stent Arterial Occlusive Diseases Clinical Trials and PubMed Articles about 4107 Zotarolimus Eluting Coronary Stent Arterial Occlusive Diseases for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of 4107 Zotarolimus Eluting Coronary Stent Arterial Occlusive Diseases Companies in our database. You can also find out about relevant 4107 Zotarolimus Eluting Coronary Stent Arterial Occlusive Diseases Drugs and Medications on this site too.

Showing "4107 Zotarolimus Eluting Coronary Stent Arterial Occlusive Diseases" Clinical Trials 1–25 of 4,500+

Extremely Relevant

RESOLUTE Japan - The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent

The objective of the study is to verify the safety and efficacy of the MDT-4107 Drug-Eluting Coronary Stent for the treatment of de novo lesions in native coronary arteries.

RESOLUTE Japan SVS: The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries

The objective of the study is To verify the safety and efficacy of the MDT-4107 Drug-Eluting Coronary Stent in the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) that allows the use of 2.25mm diameter stents.

Efficacy Study of Rapamycin- vs. Zotarolimus-Eluting Stents to Reduce Coronary Restenosis

The purpose of this trial is to evaluate the efficacy of Rapamycin- and Zotarolimus-Eluting stents for the reduction of Coronary Restenosis

Endeavor Zotarolimus - Eluting Stent in the Treatment Lesions in Small Native Coronary Arteries.

The Endeavor Zotarolimus-Eluting Coronary Stent System utilized in the ENDEAVOR SVS Registry is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo lesions of length >14 mm and < 27 mm in native coronary arteries with reference vessel diameters of > 2.25 mm to < 2.75 mm.

China Endeavor Registry: A Registry With The Endeavor Zotarolimus Eluting Coronary Stent in China

The safety and efficacy of the Endeavor(TM) Zotarolimus Eluting Coronary Stent System has been assessed in a series of studies. The stent is coated with a proprietary drug compound zotarolimus that is designed to reduce restenosis. This prospective multi-center study has been initiated: To document the acute and mid-term safety and overall clinical performance of the Endeavor(TM) Zotarolimus Eluting Coronary stent system in a "real world" Chinese patient population requ...

Randomized Trial Comparing Titan Stent With Zotarolimus-Eluting Stent

A Randomized Comparison of a Titanium-Nitride-Oxide Coated Stent (Helistent Titan2, Hexacath) With a Zotarolimus-Eluting Stent (EndeavorTm, Medtronic) for Percutaneous Coronary Intervention

Optical Coherence Tomography in Long Lesions

Increasing lesion complexity in percutaneous coronary interventions (PCI) has warranted the use of overlapping drug-eluting stents. Whether the substantial impairment of arterial healing observed at sites of overlap in preclinical pathologic studies persists in patients undergoing PCI is unknown. Consecutive patients with long lesions in native coronary vessels requiring stents in overlap are prospectively assigned to receive multiple zotarolimus eluting stents (Resolute Sprint...

Assessment of Stent Strut Coverage and Endothelial Function After Drug-Eluting Stents

The purpose of this study is to compare coronary endothelium function in patients with a zotarolimus-eluting versus a sirolimus-eluting or a everolimus-eluting stents with optical coherence tomography, vasoconstriction in response to acetylcholine, and coronary biomarker level.

Sirolimus-eluting vs Zotarolimus-eluting Stents for Chronic Total Coronary Occlusions

Primary intracoronary stent placement after successfully crossing chronic total coronary occlusions (CTO) decreases the high restenosis rate at long-term follow-up compared with conventional balloon angioplasty. Several studies have shown the efficacy of sirolimus-eluting stents in selected groups of patients. In the PRISON II study we demonstrated that sirolimus-eluting stents were superior to bare metal stents in CTO. In this prospective randomized trial, sirolimus-stent impl...

Optical Coherence Tomography for Drug Eluting Stent Safety

Increasing lesion complexity in percutaneous coronary interventions (PCI) has warranted the use of overlapping drug-eluting stents. Whether the substantial impairment of arterial healing observed at sites of overlap in preclinical pathologic studies persists in patients undergoing PCI is unknown. Consecutive patients with long lesions in native coronary vessels requiring stents in overlap are prospectively randomized to receive multiple sirolimus-,paclitaxel polymer-or zotarol...

E-Five Registry: A World-Wide Registry With The Endeavor Zotarolimus Eluting Coronary Stent

The safety and efficacy of the Endeavor(TM) ABT-578 Eluting Coronary Stent System has been assessed in a series of studies. The stent is coated with a proprietary drug compound that is designed to reduce restenosis. This prospective multi-center study has been initiated: - To document the acute and mid-term safety and overall clinical performance of the stent system in a "real world" patient population requiring stent implantation. - To assess the event rate...

YUKON-Drug-Eluting Stent Below The Knee - Randomised Double-Blind Study

The purpose of this study is to compare the effectiveness of the treatment with balloon-expandable YUKON-BTX-Sirolimus-eluting stent over the treatment with YUKON-BTX uncoated stent in patients with ischemic infrapopliteal arterial disease.

The Medtronic RESOLUTE US Clinical Trial

The objective of the study is to assess the safety and efficacy of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) of 2.25 mm to 4.2 mm.

Comparison of Neointimal Coverage Between Zotarolimus Eluting Stent and Everolimus Eluting Stent

Stent thrombosis is an important issue in drug eluting stents. Incomplete endothelial coverage and neointimal coverage over strut after drug eluting stent (DES) implantation could be a possible cause of stent thrombosis. Therefore, theoretically dual antiplatelet therapy should be continued to prevent the stent thrombosis until complete reendothelialization. But, detection of endothelial coverage over stent is not possible with the available intravascular devices in clinical pr...

Randomized Study Comparing Endeavor With Cypher Stents (PROTECT)

The PROTECT TRIAL is a randomized stent trial with 8800 patients in approximately 200 hospitals, which is designed to evaluate whether the Endeavor stent PROTECTS against late stent thrombosis resulting in less deaths and myocardial infarctions. Study Stents: Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System or next generation model Cordis Cypher® Sirolimus-eluting Coronary Stent, Cordis Cypher Select® Sirolimus-eluting Coronary Stent or next generation ...

Efficacy Study of Drug-Eluting Stents to Treat Unprotected Coronary Left Main Disease

The purpose of this study is to evaluate the efficacy of two different drug-eluting stents (Everolimus and Zotarolimus-eluting) for treatment of unprotected left main coronary artery disease.

RESOLUTE International Registry: Evaluation of the Endeavor Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population

The primary objective of the RESOLUTE international registry is to document the safety and overall clinical performance of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in a 'real-world' patient population requiring stent implantation.

Zotarolimus and Everolimus-Eluting Stents ProsPectively Compared in Real World

The zotarolimus-eluting Endeavor Resolute stent is not inferior to the everolimus- eluting Xience V stent platform regarding a composite of cardiac death, myocardial infarction or target lesion revascularisation in a real-world population.

Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions

The purpose of this study is to establish the safety and long-term effectiveness of coronary stenting with the ABT 578-eluting balloon expandable stent (Medtronic, Minneapolis, MN) vs. the sirolimus-eluting balloon expandable stent (Cordis Johnson & Johnson, Warren, New Jersey) and the paclitaxel-eluting stent (Taxus liberte, Boston Scientific) for the treatment of coronary stenosis in routine clinical practice.

Registry to Evaluate the Efficacy of Zotarolimus-Eluting Stent

The objective of this study is to evaluate the safety and long-term effectiveness of coronary stenting with the zotarolimus eluting stent (ZES) and to determine clinical device and procedural success during commercial use of ZES. The investigators will compare 2nd generation ZE (Endeavor resolute, active prospective arm) with 1st generation ZES (Endeavor Sprint, retrospective arm).

Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions

The purpose of this study is to evaluate the safety and effectiveness of the Conor Sirolimus-eluting Coronary Stent System in the treatment of coronary artery disease (a single atherosclerotic lesion) in native coronary arteries. The study will evaluate the outcomes of a new drug-eluting stent compared to an approved drug-eluting stent.

Evaluation of Zotarolimus Eluting Stent at 3 Months Using Optical Coherence Tomography

Neointimal coverage over stent strut is important for preventing the stent thrombosis. But, there is no data for the duration of complete formation of neointima om zotarolimus eluting stent (ZES). Previously the investigational observational data at 9 months showed most of stent strut was covered with neointima. Therefore, the investigators investigated the evaluation of neointimal coverage on 3 months after ZES implantation using novel OCT system, which is powerful intravascul...

A Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent Systems (GENESIS)

To demonstrate non-inferiority in 6-month angiographic in-stent late lumen loss of the pimecrolimus-eluting coronary stent (Corio) compared to the CoStar coronary stent control arm and the dual pimecrolimus/paclitaxel-eluting (Symbio) coronary stent compared to the CoStar coronary stent control arm for the treatment of single de novo lesions

Angiography Study of BioNIR Drug Eluting Stent System (NIREUS)

The NIREUS study aims to demonstrate angiographic non-inferiority for the BioNIR Ridaforolimus Eluting Coronary Stent System (hereafter referred to as BioNIR) in comparison to the Resolute zotarolimus-eluting stent (hereafter referred to as Resolute). The trial hypothesis is that the BioNIR is non-inferior to the Resolute for the primary endpoint of angiographic in-stent late loss at 6 months.

Randomized Comparison of Everolimus-Eluting Stent vs Sirolimus-Eluting Stent in Patients With DIABETES Mellitus

The purpose of this study is to establish the safety and effectiveness of coronary stenting with the Everolimus- Eluting stent compared to the Sirolimus-Eluting stent in the treatment of de novo coronary stenosis in patients with diabetic patients.


More From BioPortfolio on "4107 Zotarolimus Eluting Coronary Stent Arterial Occlusive Diseases"

Search BioPortfolio:
Advertisement
Advertisement

Clinical Trial Quicklinks